Thus, we need more treatment options. The authors also point out that Wegovy may provide added benefits by addressing the comorbidities commonly seen in people with MASH, such as cardiovascular disease and obesity, a cluster of conditions known as Its definitely exciting to have another therapeutic, said Kim
As recently as 2023, Winfrey was still struggling to justify taking a GLP-1, feeling a weight of shame and responsibility for her obesity, which she'd carried for decades
Safety Considerations and Who Should Discuss Oral Semaglutide With Their Provider Oral semaglutide is not recommended for patients with severe gastrointestinal motility disorders, history of medullary thyroid cancer, or multiple endocrine neoplasia type 2
Wang, Y., Guo, Y., Hu, Y., Sun, Y
Increasing Global Demand: With the global rise in obesity and type 2 diabetes, Semaglutide suppliers have a massive opportunity to expand their reach into emerging markets